Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
78% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CRMD' s 10-Year Cash to Debt Range
Min: 0.11  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.95
CRMD's Equity to Asset is ranked higher than
94% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRMD: 0.95 )
Ranked among companies with meaningful Equity to Asset only.
CRMD' s 10-Year Equity to Asset Range
Min: -1.36  Med: 0.71 Max: 0.95
Current: 0.95
-1.36
0.95
F-Score: 5
Z-Score: 27.87
M-Score: 5.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4760.42
CRMD's Operating margin (%) is ranked lower than
88% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CRMD: -4760.42 )
Ranked among companies with meaningful Operating margin (%) only.
CRMD' s 10-Year Operating margin (%) Range
Min: -245750  Med: -125230.03 Max: -4710.05
Current: -4760.42
-245750
-4710.05
Net-margin (%) -5861.81
CRMD's Net-margin (%) is ranked lower than
89% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CRMD: -5861.81 )
Ranked among companies with meaningful Net-margin (%) only.
CRMD' s 10-Year Net-margin (%) Range
Min: -456650  Med: -233735.85 Max: -10821.69
Current: -5861.81
-456650
-10821.69
ROE (%) -162.73
CRMD's ROE (%) is ranked lower than
89% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CRMD: -162.73 )
Ranked among companies with meaningful ROE (%) only.
CRMD' s 10-Year ROE (%) Range
Min: -899.21  Med: -528.63 Max: -158.05
Current: -162.73
-899.21
-158.05
ROA (%) -122.78
CRMD's ROA (%) is ranked lower than
87% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CRMD: -122.78 )
Ranked among companies with meaningful ROA (%) only.
CRMD' s 10-Year ROA (%) Range
Min: -507.14  Med: -196.95 Max: -117.7
Current: -122.78
-507.14
-117.7
ROC (Joel Greenblatt) (%) -36061.97
CRMD's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CRMD: -36061.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -73563.64  Med: -42382.35 Max: -35800
Current: -36061.97
-73563.64
-35800
EBITDA Growth (3Y)(%) 14.70
CRMD's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CRMD: 14.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRMD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -66.3  Med: -13.00 Max: 14.7
Current: 14.7
-66.3
14.7
EPS Growth (3Y)(%) 18.30
CRMD's EPS Growth (3Y)(%) is ranked higher than
75% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CRMD: 18.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRMD' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.4  Med: -15.70 Max: 18.3
Current: 18.3
-68.4
18.3
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

CRMD Guru Trades in Q4 2014

Paul Singer 781,440 sh (unchged)
» More
Q1 2015

CRMD Guru Trades in Q1 2015

Jim Simons 47,600 sh (New)
Paul Singer 1,500,200 sh (+91.98%)
Paul Singer 1,500,200 sh (+91.98%)
» More
Q2 2015

CRMD Guru Trades in Q2 2015

Paul Singer 1,500,200 sh (unchged)
Jim Simons Sold Out
» More
2015

CRMD Guru Trades in 2015

Paul Singer 2,373,694 sh (+58.23%)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.74
CRMD's P/B is ranked higher than
67% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CRMD: 2.74 )
Ranked among companies with meaningful P/B only.
CRMD' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 61.5
Current: 2.74
0
61.5
Current Ratio 20.26
CRMD's Current Ratio is ranked higher than
90% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CRMD: 20.26 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s 10-Year Current Ratio Range
Min: 0.1  Med: 2.89 Max: 20.26
Current: 20.26
0.1
20.26
Quick Ratio 19.89
CRMD's Quick Ratio is ranked higher than
90% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CRMD: 19.89 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s 10-Year Quick Ratio Range
Min: 0.1  Med: 2.89 Max: 19.89
Current: 19.89
0.1
19.89
Days Inventory 440.38
CRMD's Days Inventory is ranked lower than
94% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. CRMD: 440.38 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s 10-Year Days Inventory Range
Min: 72.28  Med: 147.24 Max: 222.19
Current: 440.38
72.28
222.19
Days Sales Outstanding 143.21
CRMD's Days Sales Outstanding is ranked lower than
82% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CRMD: 143.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s 10-Year Days Sales Outstanding Range
Min: 154.5  Med: 259.75 Max: 365
Current: 143.21
154.5
365

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.85
CRMD's Price/Net Cash is ranked higher than
82% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CRMD: 2.85 )
Ranked among companies with meaningful Price/Net Cash only.
CRMD' s 10-Year Price/Net Cash Range
Min: 2.11  Med: 5.14 Max: 35.14
Current: 2.85
2.11
35.14
Price/Net Current Asset Value 2.74
CRMD's Price/Net Current Asset Value is ranked higher than
82% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. CRMD: 2.74 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRMD' s 10-Year Price/Net Current Asset Value Range
Min: 2.05  Med: 4.50 Max: 31.74
Current: 2.74
2.05
31.74
Price/Tangible Book 2.74
CRMD's Price/Tangible Book is ranked higher than
73% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. CRMD: 2.74 )
Ranked among companies with meaningful Price/Tangible Book only.
CRMD' s 10-Year Price/Tangible Book Range
Min: 2.05  Med: 4.50 Max: 31.74
Current: 2.74
2.05
31.74
Price/Projected FCF 9.55
CRMD's Price/Projected FCF is ranked lower than
72% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CRMD: 9.55 )
Ranked among companies with meaningful Price/Projected FCF only.
CRMD' s 10-Year Price/Projected FCF Range
Min: 12.52  Med: 12.52 Max: 12.52
Current: 9.55
Earnings Yield (Greenblatt) (%) -25.90
CRMD's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CRMD: -25.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRMD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -34.6  Med: 0.00 Max: 0
Current: -25.9
-34.6
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 0 2 5
EPS($) -0.54 -0.28 -0.21
EPS without NRI($) -0.54 -0.28 -0.21

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CorMed Aug 07 2015 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of Clas Jul 16 2015 
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action... Aug 31 2015
GPM Reminds Investors of the September 4, 2015 Deadline in the Class Action Lawsuit On Behalf Of... Aug 31 2015
CorMedix Inc. Abstracts Accepted for Presentation at American Society of Nephrology Kidney Week 2015 Aug 31 2015
September 4 Deadline in Lawsuit for Investors in CorMedix Inc. (NYSE MKT:CRMD) Shares Announced by... Aug 31 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of CorMedix, Inc. of Pendency of Class... Aug 26 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Aug 24 2015
IMPORTANT INVESTOR DEADLINE: Goldberg Law PC Reminds Investors With Losses in Excess of $50,000 in... Aug 21 2015
SECURITIES ALERT: Rosen Law Firm Reminds CorMedix, Inc. Investors of the Important Deadline in the... Aug 20 2015
GPM Announces The Filing Of A Securities Class Action On Behalf Of CorMedix, Inc. Investors Aug 20 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against... Aug 18 2015
CORMEDIX INC. Financials Aug 18 2015
Law Offices of Howard G. Smith Announces That a Class Action Has Been Filed on Behalf of CorMedix,... Aug 17 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of... Aug 17 2015
Exclusive: Elliott's Paul Singer Says Rumors Of Yahoo Position Are Not True Aug 13 2015
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Aug 13 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving... Aug 12 2015
Paul Singer’s Elliott Management Ups Stake In CorMedix Inc. (CRMD) Aug 12 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Aug 07 2015
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Aug 07 2015
CorMedix Inc. Announces Janet D. Dillione Will Join Board of Directors Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK